Skip to main content
. 2016 Oct 12;16:562. doi: 10.1186/s12879-016-1894-3

Table 1.

Baseline characteristics of the study populationa

Variable Level n (%)
N (%) 1815 (100)
Lusaka 1111 (61.2)
Age (years), median (IQR) 35 (29–41)
Female 900 (49.6)
BMI (kg/m2), median (IQR) 16.7 (15.6–17.5)
BMI <17 kg/m2 1074 (59.2)
CD4 count (cells/μl), median (IQR) 120 (51–211)
CD4 count group > = 200 494 (27.2)
100–199 531 (29.3)
50–99 347 (19.1)
<50 443 (24.4)
Haemoglobin (g/L), median (IQR) 96 (80–111)
Haemoglobin groupb Normal 177 (9.8)
Mild anaemia 285 (15.7)
Moderate anaemia 810 (44.6)
Severe anaemia 398 (21.9)
Missing 145 (8.0)
Phosphate <0.87 mmol/L <0.87 196 (10.8)
Missing 51 (2.8)
Marital status Married/Cohabiting 858 (47.3)
Widowed 203 (11.2)
Divorced-Separated 510 (28.1)
Single 243 (13.4)
Missing 1 (<0.1)
Occupation Salaried 271 (14.9)
Self-employed 945 (52.1)
Housewife 183 (10.1)
Student 18 (1.0)
Unemployed 397 (21.9)
Missing 1 (<0.1)
Education None 343 (18.9)
Primary 1045 (57.6)
Secondary 377 (20.8)
Tertiary 49 (2.7)
Missing 1 (<0.1)
TB treatment at baseline 304 (16.9)
Oedema at baseline 66 (3.6)
Initial ART regimen (% of 1474 patients who started ART) AZT/3TC/EFV 135 (9.2)
AZT/FTC/NVP 236 (16.0)
TDF/FTC/EFV 816 (55.4)
TDF/FTC/NVP 64 (4.3)
Other 54 (3.7)
Missing 169 (11.5)

a BMI body mass index, CI confidence interval, LNS lipid-based nutritional supplement without added vitamins and minerals, LNS-VM lipid nutritional supplement with added vitamins and minerals, AZT Zidovudine, 3TC Lamivudine, NVP nevirapine, TDF tenofovir, EFV efavirenz; FTC emtricitabine

bHaemoglobin categories were selected based on usual nutritional cut-offs, not as defined for specific adverse events; adequate haemoglobin was defined as 130 g/L for men and 120 g/L for women; mild anaemia was 110 g/L to the adequate cut-off; moderate anaemia was 80–109 g/L; severe anaemia was < 80 g/L